Titan Pharmaceuticals (NASDAQ:TTNP) signed a pharmacy services agreement with Southside Specialty Pharmacy, further expanding access to treatment with Probuphine (buprenorphine) implant, Titan’s unique maintenance treatment for Opioid Use Disorder (OUD) in eligible patients.
Titan’s strategic expansion of its specialty pharmacy network is a key component of its focused commercialization strategy for Probuphine.
“We are pleased to add Southside as one of Titan’s valued specialty pharmacy partners, particularly given its strong presence in important markets in California and Texas,” Titan’s chief commercial officer, Dane Hallberg, said in a statement.
Titan expects the majority of Probuphine sales in the U.S. to be through the specialty pharmacy distribution model, where a specialty pharmacy carries inventory, directly handles the subsequent patients’ insurance billing and payment processes, and ships to the healthcare provider as prescribed.
“This partnership with Southside adds regional strength and reflects our ongoing effort to expand our network with additional well-established specialty pharmacies,” said Hallberg.
Titan inked specialty pharmacy agreements with AllianceRx Walgreens Prime in February 2019 and Accredo specialty pharmacy, a subsidiary of Express Scripts, in May 2019.
